Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression

Ai-Tram N Bui; Caroline A Nelson; Christine G Lian; Alvaro Laga Canales; Nicole R LeBoeuf

doi:10.1016/j.jdcr.2020.04.010

Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression

JAAD Case Rep. 2020 Apr 25;6(8):693-696. doi: 10.1016/j.jdcr.2020.04.010. eCollection 2020 Aug.

Authors

Ai-Tram N Bui¹, Caroline A Nelson², Christine G Lian³, Alvaro Laga Canales³, Nicole R LeBoeuf^{4

5}

Affiliations

¹ Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
³ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

No abstract available

Keywords: EF, eosinophilic fasciitis; ICI, immune checkpoint inhibitor; MRI, magnetic resonance imaging; PD-1/L1 inhibition; PFTs, pulmonary function tests; ROM, range of motion; autoimmunity; checkpoint inhibition; cutaneous toxicities; eosinophilic fasciitis; immune checkpoint inhibitors; immune-related adverse event; irAE, immune-related adverse event.

Publication types

Case Reports

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States